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SV40Repression of human papillomavirus (HPV) E6 and E7 oncogenes in established cervical carcinoma cell lines
causes senescence due to reactivation of cellular tumor suppressor pathways. Here, we determinedwhether on-
going expression of HPV16 or HPV18 oncogenes is required for the proliferation of primary human cervical car-
cinoma cells in serum-free conditions at low passage number after isolation frompatients.Weused an SV40 viral
vector expressing the bovine papillomavirus E2 protein to repress E6 and E7 in these cells. To enable efﬁcient
SV40 infection and E2 gene delivery, we ﬁrst incubated the primary cervical cancer cells with the ganglioside
GM1, a cell-surface receptor for SV40 that is limiting in these cells. Repression of HPV in primary cervical carci-
noma cells caused them to undergo senescence, but the E2 protein had little effect on HPV-negative primary
cells. These data suggest that E6 and E7 dependence is an inherent property of human cervical cancer cells.
© 2011 Elsevier Inc. All rights reserved.Introduction
Cervical carcinoma is initiated by infection with high-risk human
papillomaviruses (HPV) such as HPV16 or 18 (Bosch et al., 2002). Ex-
pression of the HPV E6 and E7 oncogenes can immortalize primary, cul-
tured human keratinocytes, the cells that give rise to cervical
carcinomas (Durst et al., 1987; Hawley-Nelson et al., 1989; Hudson et
al., 1990; Munger et al., 1989; Pirisi et al., 1987), and estrogen-treated
transgenic mice expressing HPV16 E6 and E7 develop cervical carcino-
mas (Arbeit et al., 1996). High-risk HPV E6 binds to p53, a tumor sup-
pressor, and stimulates its ubiquitin-mediated degradation (Howie et
al., 2009). High-risk HPV E7 binds to the p105Rb and other members
of the retinoblastoma (Rb) family, causing their dissociation from E2F
proteins and degradation of the active hypophosphorylated form of
p105Rb, releasing E2F to activate genes required for cell cycle progres-
sion (Moody and Laimins, 2010). Transcription of E6 and E7 can be re-
pressed by the papillomavirus E2 protein, which binds to the HPV E6/
E7 promoter in the long control region of the viral genome (Thierry
and Yaniv, 1987). Viral DNA integration or mutations that interfereYale School of Medicine, P.O.
203 785 6765.
.
rights reserved.with expression or activity of the E2 protein frequently occur during
cervical carcinogenesis, leading to elevated expression of E6 and E7
(May et al., 1994; Schneider-Maunoury et al., 1987), which are contin-
uously expressed in cervical carcinoma cell lines (Baker et al., 1987;
Schwarz et al., 1985).
The proliferation and survival of cervical cancer cell lines requires on-
going expression of E6 and E7. Introduction of the HPV or bovine papillo-
mavirus (BPV) E2 gene or siRNAs against HPV E6 and E7 inhibits the
proliferation of cervical carcinoma cell lines or causes apoptosis
(Desaintes et al., 1997; Dowhanick et al., 1995; Hwang et al., 1993;
Jiang and Milner, 2002; McBride et al., 1991; Parish et al., 2006). Repres-
sion of HPV18 E6 and E7 by BPV-E2 in HeLa cervical cancer cells results in
growth arrest and cellular senescence due to reactivation of the p53 and
Rb tumor suppressor pathways (Goodwin andDiMaio, 2000; Goodwin et
al., 2000; Wells et al., 2000). Similarly, in a transgenic mouse model, re-
pression of E7 expression driven by a tetracycline-regulated promoter
leads to regression of high-grade cervical dysplasia and tumors (Jabbar
et al., 2009). However, murine keratinocytes differ in some regards
from their human counterparts (Balmain and Harris, 2000; Chaturvedi
et al., 2004; Dotto, 1998), and cervical carcinogenesis in mice differs in
certain aspects from human carcinogenesis. For example, the latency pe-
riod of tumor formation in these mice is measured in months, whereas
decades typically pass in women between HPV infection and the
Table 1
Characteristics of primary cervical carcinoma cells.
Cell name HPV type Passage numbera Histologyb Stageb,c Disease siteb
HeLa 18 –d AD –e Cervix
SiHa 16 –d SCC II Cervix
CaSki 16 –d SCC REC Metastatic SBM
101 16 39 SCC IB Cervix
102 16 16 SCC IB Cervix
104 18 33 AD IB Cervix
106 16 3 SCC IB Cervix
a A passage number indicates the earliest passage number at which the effect of E2
expression on growth was measured.
b SCC, squamous cell carcinoma; AD, adenocarcinoma; REC, recurrent disease; SBM,
small bowel mesentery.
c Staging for primary isolates was done according to the Figo staging system.
d The passage number for cell lines is not known. Cell lines were isolated in 1951
(HeLa), 1970 (SiHa), and 1977 (CaSki).
e The cancer stage is not known.
115T.G. Magaldi et al. / Virology 422 (2012) 114–124development of invasive cancer. It is thought that additional cellular mu-
tations accumulate in infected human cells during this protracted latency
period. Nevertheless, the fact that human cervical carcinoma cell lines
and tumors in transgenicmice depend onHPV oncogene expression sug-
gests that the E6 and E7 genes are potential targets for treatment of
human cervical carcinoma.
It is not known whether dependence on E6 and E7 is an inherent
property of human cervical carcinoma cells or whether this trait is ac-
quired during the establishment or propagation of continuous cell
lines. Continuous cell lines can be established from only a minority
of primary tumors, and several pieces of evidence indicate that estab-
lished cancer cell lines are not necessarily representative of the tumor
of origin (Bignotti et al., 2006; Dairkee et al., 2004; Ertel et al., 2006;
Lee et al., 2006; Santin et al., 2004; van Staveren et al., 2007; van
Staveren et al., 2009). For example, analysis of gene expression pro-
ﬁles of the 60 cancer cells lines in the NC60 panel revealed only a 5
percent overlap in up-regulated genes compared to their correspond-
ing tumor tissue (Sandberg and Ernberg, 2005). In addition, a com-
prehensive microarray-based analysis of cervical cancers and
cervical cancer cell lines demonstrated that cervical cancers were
more similar to normal primary cervical epithelial cells than they
were to cervical cancer cell lines, indicating that the transcriptional
changes that occur during the transition of normal cells to cancer
cells are less pronounced than the changes that occur during the con-
version of cancer cells into established cell lines (Carlson et al., 2007).
These problems are a particular concern for cervical cancer cell lines,
most of which have been in culture for decades (60 years in the case
of HeLa cells). Thus, if a small population of cells that was dependent
upon E6 and E7 possessed even a slight growth advantage in vitro, or if
E6/E7-dependent cells were more likely to accumulate mutations that
conferred a growth advantage during in vitro culture, these cells would
eventually overgrow the culture, giving rise to a cell line that has diverged
from its tumor of origin in terms of its oncogene dependence. In fact, HPV
E6 and E7 engender a state of genomic instability and increasedmutagen-
esis, which provides an accelerated path for cell lines to diverge from the
original cancer (Moody and Laimins, 2010).
It might be expected that cells transformed by HPV in infected
women would initially depend on the E6 and E7 oncogenes, and that
the accumulation of mutations as the lesions progress in vivo or the
cells are passaged in culture is likely to gradually render the cells inde-
pendent of growth regulatory signals, so that they lose a requirement
for E6 and E7. On the other hand, it is also possible that cancer cells
do not require a particular oncogene for continued proliferation in cul-
ture until they are passaged in vitro. For example, in studies of a lung
cancer cell line dependent on a mutant epidermal growth factor recep-
tor, Turke et al. showed that in vitro culture of these cells in the presence
of hepatocyte growth factor can generate cells that require continued
signaling by c-Met, the hepatocyte growth factor receptor, as well as
the EGF receptor (Turke et al., 2010). Published reports suggest a mech-
anism by which HPV E6/E7 could confer a growth advantage to cervical
cancer cell lines cultured in vitro. Cervical carcinoma cell lines are typi-
cally maintained in high concentrations of calcium and fetal bovine
serum (FBS). These conditions induce terminal differentiation of prima-
ry human keratinocytes and growth arrest. However, high-risk HPV E6
and E7 expression inhibits terminal differentiation of primary human
keratinocytes and allows a small fraction of cells to proliferate in the
presence of calcium and FBS (Munger et al., 1989; Pei et al., 1998;
Schlegel et al., 1988; Sherman and Schlegel, 1996). Therefore, the stan-
dard conditions used to culture cell lines may have selected for expres-
sion of E6 and E7 to prevent terminal differentiation. If this were the
case, the demonstrated requirement for E6/E7 in cell lines might reﬂect
the ongoing need of these genes to continuously block terminal differ-
entiation in response to serum and calcium in vitro, rather than an in-
trinsic growth property of the cells.
To minimize the risk of selection or genetic drift in testing the re-
quirement for E6 and E7 in cervical cancer cells, we decided to assessthe requirement for E6 and E7 in primary cultures of human cervical
carcinoma cells. In work published by us and by others, gene expres-
sion proﬁling showed that various types of unmanipulated tumors
are more similar to low passage primary cancer cells than they are
to established cell lines derived from the same tumors (Bignotti et
al., 2006; Dairkee et al., 2004; Lee et al., 2006; Santin et al., 2004).
Thus, not surprisingly, primary cervical cancer cells are more repre-
sentative of the original tumors than are long-term, established cell
lines. There is a previous report that expression of BPV-E2 inhibited
DNA synthesis in three early passage cervical carcinoma cell lines con-
tainingHPV16DNA (Moon et al., 2001), but these cells were established
andmaintained in high calcium and FBS, somay have been subjected to
selective pressure for E6/E7 dependence as described above.
In the experiments reported here, we isolated primary cancer cells
from tumor biopsies of four patients with cervical carcinoma and cul-
tured them for a minimal number of passages in low concentrations
of calcium and in the absence of serum to prevent terminal differen-
tiation and in vitro selection for E6/E7 dependence. For these experi-
ments, we wished to use an SV40 recombinant virus vector to express
the BPV-E2 protein, because this is an extremely efﬁcient system to
repress E6 and E7 in HeLa cells. However, most cells we tested
infected poorly with this vector. By exploiting our understanding of
factors that mediate SV40 infection, we were able to markedly en-
hance infection by the SV40 vector by treating the cells with the gan-
glioside GM1, a cellular receptor of SV40 (Tsai et al., 2003), prior to
infection. GM1 added to the culture medium is incorporated into
the plasma membrane (Schwarzmann, 2001), thus increasing the
cell surface GM1 that can be used by SV40 for infection. By using
this approach, we demonstrated that primary cervical carcinoma
cells are indeed dependent on E6 and E7 for continued growth.
Results
Isolation of primary human cervical carcinoma cells
Primary cervical carcinoma cells were isolated from surgical biop-
sies as described previously (Santin et al., 2005) and cultured in
serum-free keratinocyte medium, which contains low concentrations
of calcium to prevent differentiation. Characteristics of these cells in-
cluding the resident HPV DNA type are summarized in Table 1. Pas-
sage 0 is the point at which cells were initially placed in culture,
and one passage number was recorded each time a 70–80% conﬂuent
dish of cells was passed. The passage number at which each isolate
was analyzed in various experiments is indicated where relevant in
the ﬁgures. All primary cervical carcinoma isolates were conﬁrmed
to express dramatically elevated levels of p16ink4a mRNA, a marker
of cervical cancer (Sano et al., 1998), when compared to primary ker-
atinocytes and ﬁbroblasts (data not shown).
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HeLa-Sen2 cells
Exogenous expression of the BPV E2 gene (designated E2) in sev-
eral different established cervical carcinoma cell lines causes irrevers-
ible growth arrest and senescence due to transcriptional repression of
the HPV E6 and E7 genes (Goodwin et al., 2000; Wells et al., 2000).
Previously we used an SV40-based recombinant virus vector (desig-
nated Pava) to express the wild-type (WT) E2 gene in HeLa-Sen2
cells, a strain of HeLa cells that is efﬁciently infected with this virus
(Goodwin et al., 2000; Hwang et al., 1993). In this vector, the SV40
large T antigen gene is replaced with the E2 gene, but the SV40 capsid
protein genes are retained. Replication-defective Pava virus particles
containing the E2 gene packaged in an SV40 capsid are generated in
permissive monkey CMT4 cells, which supply SV40 replication func-
tions in trans (Settleman and DiMaio, 1988). Infection of HeLa-Sen2
cells with Pava delivers the E2 gene into essentially every cell,
which leads to profound repression of E6/E7 and a rapid induction
of senescence (Goodwin et al., 2000). Strikingly, although Pava
caused dramatic growth arrest in HeLa-Sen2 cells, it had little or no
effect on DNA synthesis of CaSki and SiHa cells, two cervical carcino-
ma cell lines that contain HPV16 DNA (Fig. 1A, gray bars). PavaFig. 1. Effect of GM1 on SV40 infection of cervical carcinoma cell lines. A) Cells were left un
infected or infected with Pava at an MOI of 20. At 48 h post-infection, DNA synthesis was m
tiated thymidine incorporation in infected cells relative to mock-infected cells. The results
Similar results were obtained in at least three independent experiments. B) Cells were left un
at an MOI of 10. The fraction of cells expressing large T antigen was measured by immunost
independent experiments. C) Cells were left untreated (top panel) or treated with GM1 ov
binding of ﬂuorescently-labeled CTXB. The dotted red lines represent SiHa cells incubated i
periments. D) Cells were left untreated (gray bars) or treated with GM1 overnight (white
infection, HPV18 E6/E7 mRNA levels in HeLa-Sen2 cells and HPV16 E6/E7 mRNA levels in Si
E7 expression is reported as fold-reduction in the level of mRNA in infected cells relative to m
average of triplicate samples. Similar results were obtained in two independent experimeninfection also failed to inhibit DNA synthesis of all primary cervical
carcinoma isolates tested, except CVX-102 (data not shown).
WT SV40 and Pava infection of established cervical carcinoma cell lines
Because the introduction of the E2 gene into CaSki and SiHa cells
by transfection or adenovirus vectors leads to growth arrest (Lee et
al., 2002; Wells et al., 2000), we hypothesized that the SV40-based
vector used to deliver the E2 gene did not efﬁciently infect
these cells. In order to test this hypothesis, we measured the ability
of WT SV40 to infect the three established cervical cancer cell lines.
HeLa-Sen2, CaSki, and SiHa cells were infected with SV40 at an MOI
of 10 (titer determined in permissive monkey cells), and infection
was measured by immunostaining and ﬂow cytometry of large T an-
tigen expression. Typical histograms of ﬂow cytometry data are pre-
sented in supplementary Figure S1. As predicted, more than 90
percent of HeLa-Sen2 cells expressed large T antigen (Fig. 1B, gray
bars). However, less than 25 percent of CaSki or SiHa cells expressed
large T antigen at this MOI. The inability of SV40 to efﬁciently infect
SiHa and CaSki cells suggests that these cells also infect poorly with
Pava, providing an explanation to their resistance to Pava-induced
growth arrest.treated (gray bars) or treated with GM1 overnight (white bars) and then either mock-
easured by incorporation of tritiated thymidine and is presented as the percent of tri-
of a typical experiment are presented, and represent the average of triplicate samples.
treated (gray bars) or treated with GM1 overnight (white bars) and infected with SV40
aining and ﬂow cytometry at 48 h post-infection. Similar results were obtained in three
ernight (bottom panel), and GM1 surface levels were measured by ﬂow cytometry of
n the absence of CTXB. Similar results were obtained in at least three independent ex-
bars), and either mock-infected or infected with Pava at an MOI of 20. At 48 h post-
Ha and CaSki cells were measured by qRT-PCR and normalized to GAPDH mRNA levels.
ock-infected cells. The results of a typical experiment are presented, and represent the
ts.
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was a consequence of low levels of GM1, a cellular receptor used by
SV40 (Tsai et al., 2003), on the surface of these cells. To test the levels
of GM1 at the surface of cervical carcinoma cell lines, GM1 surface ex-
pression was measured with ﬂuorescently-labeled cholera toxin B
(CTXB), a bacterial toxin subunit which binds to GM1 (Chinnapen et
al., 2007). Binding to intact cells was conducted at 4 °C to prevent in-
ternalization and was measured by ﬂow cytometry. SiHa and CaSki
cells showed markedly lower levels of CTXB binding than HeLa-
Sen2 cells (Fig. 1C, top), consistent with our suggestion that low
levels of surface GM1 may limit SV40 infection in SiHa and CaSki
cells. Addition of GM1 to the culture medium of murine cells that
lack endogenous GM1 results in the incorporation of GM1 into the
plasma membrane and a dramatic increase in the number of cells sus-
ceptible to SV40 infection (Schwarzmann, 2001; Tsai et al., 2003). As
shown in Fig. 1C, bottom, addition of GM1 increased CTXB binding in
Hela-Sen2, CaSki, and SiHa cells so that the level of CTXB binding was
high in all cell lines.
We then tested whether elevating GM1 surface levels increased the
ability of SV40 to infect CaSki and SiHa cells. Cells were treated with
GM1 or left untreated. After washing away unincorporated GM1, cells
were infected with SV40 at an MOI of 10, and infection was measured
by assessing large T antigen expression by ﬂow cytometry. As shown
in Fig. 1B (white bars), increasing the level of cell surface GM1 dramat-
ically increased the ability of SV40 to infect CaSki and SiHa cells. In order
to determine whether incorporation of GM1 also increased Pava infec-
tion, we measured E2 mRNA levels in untreated or GM1-treated cells.
Pava-infected CaSki and SiHa cells displayed increased E2 mRNA ex-
pression after treatment with GM1, indicating that GM1 addition to
cells increased Pava infection (Fig. S2.)
We alsomeasured the effect of increased Pava infection on cell phys-
iology. E2 expression in GM1-treated cells led to a 6- to 20-fold repres-
sion of HPV16 E6/E7 mRNA in CaSki and SiHa cells when compared to
infected, untreated cells (Fig. 1D). We next tested whether Pava infec-
tion inhibited the DNA synthesis of GM1-treated cells. In contrast to
the minimal effects of Pava infection in native CaSki and SiHa cells, in-
fection of these cells with Pava following GM1 treatment led to a sub-
stantial repression of DNA synthesis to less than 3% of the mock-
infected cells (Fig. 1A, white bars). Pava infection of GM1-treated
CaSki and SiHa cells also led to a loss of the inactive hyperphosphory-
lated form of p105Rb and an increase in the active hypophosphorylated
form (Fig. S3). Pava infection also increased total levels of p53 protein in
CaSki cells (Fig. S3). The effects are more pronounced after GM1 addi-
tion. Although E2 expression did not appear to increase p53 levels in
SiHa cells, an increase in p53 may occur prior to the 48 h time point at
which protein was harvested (Goodwin and DiMaio, 2000). Taken to-
gether, these results indicated that the range of cells susceptible to efﬁ-
cient infection by SV40 and SV40 vectors can be expanded by addition
of GM1. Therefore,we testedwhetherwe could use this approach to ex-
press E2 in primary cervical carcinoma cells to determine the effect of
E6 and E7 repression on cell growth.
SV40 infection of primary cervical carcinoma cells
We ﬁrst used CTXB binding to measure GM1 surface expression in
four HPV-positive primary human cervical carcinoma cell isolates and
two primary cell isolates that lack HPV DNA, human foreskin ﬁbro-
blasts (HFF) and keratinocytes (HFK). As shown in the top panels of
Fig. 2A, these cells displayed a wide range of GM1 surface expression.
Addition of GM1 to the culture medium caused a marked increase in
CTXB binding in all cells tested except CVX-102 cells, which displayed
high basal CTXB binding (Fig. 2A). SV40 infection was measured as
described above in untreated cells or cells treated with GM1. The
high levels of endogenous GM1 in CVX-102 cells allowed efﬁcient
SV40 infection even without GM1 addition. In all other cell isolates,
addition of GM1 to cells caused a dramatic increase in the fractionof cells expressing large T antigen after infection, approaching 90%
in most cases (Fig. 2B).
Effect of E2 expression on DNA synthesis by primary cervical carcinoma cells
Improved SV40 infection allowed us to investigate the effect of E2
expression on the proliferation of primary cervical carcinoma cells.
HPV negative HFFs and HFKs were infected in parallel as controls.
Cells were ﬁrst treated with GM1 overnight to maximize Pava infection
and delivery of the E2 gene. After removing unincorporated GM1, cells
were infected with Pava, and DNA synthesis was measured 48 h post-
infection. Expression of E2 caused a 6–20 fold reduction in DNA synthe-
sis in the primary carcinoma cell lines tested, but had a minimal effect
on DNA synthesis in HPV-negative cells (Fig. 3A). qRT-PCR of E2
mRNA levels demonstrated that differences in E2 expression did not
dictate differences in DNA synthesis among the cell lines, because
HFKs expressed at least as much E2 mRNA as any of the primary carci-
noma cells (Fig. S4). These results indicated that growth arrest induced
by E2 expression is speciﬁc to HPV-positive cells.
To begin to determine whether the observed repression of DNA
synthesis was the result of E6 and E7 repression in primary cervical
carcinoma cells, CVX-101, CVX-104, HFF, and HFK were treated with
GM1 and infected with Pava expressing the WT E2 protein or an E2
mutant, K339M, defective for DNA binding. Reduced DNA binding
by K339M E2 inhibits transcriptional repression of E6 and E7
(Goodwin et al., 1998; Prakash et al., 1992). The K339M E2 protein
had little effect on DNA synthesis in CVX-101 and 104 cells when
compared to the WT E2 protein, suggesting that the DNA binding ac-
tivity of E2 is required for its ability to induce growth arrest (Fig. 3B).
Similar results were also obtained with CVX-102 cells (data not
shown). Neither WT nor K339M E2 caused signiﬁcant inhibition of
DNA synthesis in HPV-negative cells. The minor inhibition observed
in HFKs suggested that Pava infection and/or E2 expression caused a
minor, non-speciﬁc inhibition of DNA synthesis in HPV-negative
cells, independent of the DNA binding activity of the E2 protein
(Desaintes et al., 1999) (Fig. 3B). qRT-PCR for E2 mRNA expression
conﬁrmed that differences in growth inhibition between cells
infected with WT or K339M Pava were not the result of differences
in E2 mRNA levels, because K339M E2 mRNA levels were approxi-
mately equal to or greater than that of WT E2 (Fig. S5). Taken togeth-
er, these data imply that the growth repression caused by E2
expression in primary cervical carcinoma cells is dependent upon
the transcriptional repressor activity of the E2 protein and is likely
the result of E6 and E7 repression.
In order to test whether earlier passage cells were also dependent
on E6 and E7 for growth, we measured the effect of the E2 protein on
CVX-106 cells at passage 3. Cells were treated with GM1 and infected
with Pava expressing the WT or K339M E2 protein as described
above. Due to the limiting number and slow growth of these early
passage cells, DNA synthesis was measured at 72 h post infection in
order to maximize the effect of E2 expression on growth. Even at
these very early passages, WT E2 repressed DNA synthesis to a sub-
stantially greater degree than K339M E2 (Fig. 3C). These data indicat-
ed that extremely early passage primary cervical carcinoma cells are
also dependent on E6 and E7 for continued growth.
Effect of the E2 protein on E6 and E7 expression and activity in primary
cervical carcinoma cells
To determine whether the WT E2 protein repressed E6 and E7
mRNA expression in primary carcinoma cells, qRT-PCR was used to
measure endogenous HPV mRNA levels in two representative cervical
carcinoma cell strains, CVX-104 and CVX-106. WT E2 repressed en-
dogenous levels of HPV18 E6/E7 17-fold in CVX-104 cells and
HPV16 E6/E7 levels 15-fold in CVX-106 cells, where as K339M E2
failed to repress 18E6/E7 in CVX-104 cells and repressed 16E6/E7
Fig. 2. Effect of GM1 on SV40 infection of primary cervical carcinoma cells. A) The indicated cells were left untreated (top panels) or treated with GM1 overnight (bottom panels),
and GM1 surface expression was measured by ﬂow cytometry of binding of ﬂuorescently-labeled CTXB. Dotted red lines represent ﬂuorescence of HFK (left panels) or CVX-101 cells
(right panels) incubated in the absence of CTXB. Similar results were obtained in two independent experiments. B) The indicated cell strains were left untreated (gray bars) or trea-
ted with GM1 overnight (white bars) and infected with SV40 at an MOI of 10. The fraction of cells expressing large T antigen was measured as is described in Fig. 1B. Similar results
were obtained in two independent experiments.
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whether repression of E6 and E7 by E2 led to the reactivation of the
p105Rb and p53 tumor suppressor pathways in primary carcinoma
cells, protein was isolated from infected and mock-infected CVX-
104 and CVX-106 cells and analyzed by immunoblotting. WT E2
caused an increase in p53 levels and the hypophosphorylation/
activation of p105Rb in CVX-104 and CVX-106 cells, but K339M had
no effect on p53 levels and/or the phosphorylation state of p105Rb
(Fig. 4B). These results indicated that repression of E6 and E7 by the
E2 protein led to the reactivation of p53 and p105Rb pathways in pri-
mary cervical carcinoma cells.
Repression of E6 and E7 in primary cervical carcinoma cells induces
senescence
Repression of HPV E6 and E7 in HeLa and other established cervical
carcinoma cell lines induces senescence, a form of irreversible growth
arrest (Campisi and d'Adda di Fagagna, 2007; Goodwin et al., 2000;
Wells et al., 2000). One biomarker used to distinguish senescence
from other forms of growth arrest is an increase in senescence-
associated (SA)-β-galactosidase activity (Dimri et al., 1995). In orderto determine whether repression of E6 and E7 induced senescence
in primary cervical carcinoma cells, CVX-104, CVX-106, and HFK cells
were treated with GM1 and infected with Pava. To decrease the
number of cells that escaped infection, cells were treated with GM1
and infectedwith Pava a second time. Nine days after the initial Pava in-
fection, SA-β-galactosidase activity was assessed by staining with a
colorimetric substrate. WT E2 expression increased SA-β-
galactocidase staining in CVX-104 and 106 cells but not in HPV-
negative HFK cells (Fig. 5A). Cells that expressed SA-β-galactocidase
also displayed an enlarged and ﬂattened morphology, which is charac-
teristic of senescent cells (Fig. 5A). As expected, K339M E2 did not in-
duce SA-β-galactosidase activity or these morphological changes,
suggesting that these effects required repression of E6 and E7.
In addition to increased SA-β-galactosidase activity, senescence is
also characterized by an increase in autoﬂuorescence due to the accu-
mulation of the ﬂuorescent pigment lipofuscin (von Zglinicki et al.,
1995). Following two rounds of GM1 treatment and infection with
Pava, autoﬂuorescence was measured by ﬂow cytometry seven days
after the initial infection with Pava (Fig. 5B). WT E2 and K339M E2 ex-
pression had no effect on autoﬂuorescence in HFK cells, which contin-
ued to proliferate. Expression of the WT E2 protein, but not K339M
Fig. 3. The WT E2 protein inhibits DNA synthesis in primary carcinoma cells. A) The indicated cell strains were treated with GM1 overnight and either mock-infected or infected
with Pava at an MOI of 10. DNA synthesis was measured as in Fig. 1A and is presented as the percent of tritiated thymidine incorporated in infected cells relative to mock-
infected cells. The numbers in parentheses indicate the passage at which the cells were tested. The results of a typical experiment are shown, and represent the average of triplicate
samples. Asterisks indicate a signiﬁcant difference between DNA synthesis of mock and infected cells (*pb .05). Similar results were obtained in at least four independent experi-
ments. B) Cells were treated with GM1 in panel A and infected with Pava encoding WT (black bars) or K339M (gray bars) E2 at an MOI of 10. DNA synthesis was measured and is
presented as in panel A. The brackets indicate a signiﬁcant difference between DNA synthesis of cells infected with WT or K339M-E2 (*pb .005). Similar results were obtained in at
least four independent experiments. C) Cells were treated with GM1 and infected with WT or mutant Pava as in panel A. DNA synthesis was measured 72 h post-infection and is
presented as in panel A. The brackets indicate a signiﬁcant difference between DNA synthesis of cells infected with WT or K339M E2 (*pb .02). Similar results were obtained in two
independent experiments.
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104 and CVX-106 cells. Although a subpopulation of CVX-104 cells dis-
played low autoﬂuorescence, we believe that these are cells that es-
caped infection with Pava and continued to proliferate during the
seven day course of the experiment. This proliferating population isFig. 4. TheWT E2 protein represses E6 and E7 and activates p53 and p105Rb in primary cer-
vical carcinoma cells. A) Cells were treated with GM1 and either mock-infected or infected
with Pava encoding WT (black bars) or K339M (gray bars) E2 at an MOI of 10. At 40 h
post-infection, levels of HPV18 E6/E7 (CVX-104) and HPV16 E6/E7 (CVX-106) mRNA were
measured and reported as described in Fig. 1D. The passage numbers at which the cells
were tested are indicated in parentheses. Similar results were obtained in three independent
experiments. B) Cellswere treatedwithGM1and eithermock-infected or infected as inpanel
A. Proteinwas harvested at 48 h post-infection and analyzed by SDS-PAGE and immunoblot-
ting for p105Rb, p53, and actin (loading control). P indicates hyperphosphorylated p105Rb,
while O indicates active, hypophosphorylated p105Rb. Similar results were obtained in
three independent experiments.not seen in CVX-106 cells. However, since CVX-106 cells grow signiﬁ-
cantly slower than CVX-104 cells (data not shown), cells that escaped
infection would still be a very minor fraction at day seven post-
infection. Taken together, these data demonstrated that repression of
E6 and E7 induces senescence in primary cervical carcinoma cells.
Exogenous expression of E6 and E7 in CVX-104 cells impairs growth arrest
induced by E2 expression
We performed a gene rescue experiment to conﬁrm that the phe-
notypes elicited by Pava infection in primary cervical carcinoma cells
were due to E6/E7 repression. CVX-104 cells were infected either
with an empty retroviral vector or the vector encoding HPV16 E6
and HPV18 E7. Since these genes are expressed from the retroviral
LTR, E2 does not affect their expression. After conﬁrming expression
of these genes by qRT-PCR (data not shown), the cells were treated
with GM1 and infected with Pava. Growth arrest was then measured
by DNA synthesis. As shown in Fig. 6A, expression of exogenous
HPV16 E6 and 18 E7 largely abrogated the inhibition of DNA synthesis
caused by E2 expression in these cells. qRT-PCR conﬁrmed that Pava-
infected 16E6/18E7 expressing cells contained at least the same
amount of E2 mRNA as infected control cells (data not shown). qRT-
PCR using primers speciﬁc for the endogenous or exogenous E6/E7
transcripts conﬁrmed that expression of the endogenous E6 and E7
genes in 16E6/18E7 cells was repressed by Pava infection to at least
the same level seen in control cells (Fig. 6B), but expression of the ex-
ogenous E6/E7 genes was not affected (data not shown). Similarly, as
measured by autoﬂuorescence and granularity, which are both in-
creased during senescence, there was a four- to ﬁve-fold reduction
in the number of CXV-104 16E6/18E7 cells that senesced following
Pava infection compared to infected control CVX-104 cells (Fig. S6).
These data showed that E2-induced growth arrest and senescence
in CVX-104 cells was the result of E6 and E7 repression.
Discussion
The experiments reported here demonstrate that HPV oncogene
expression is required for the proliferation of primary human cervical
cancer cells in culture and provide insight into factors that control
tropism of SV40 and SV40-based vectors. Numerous laboratories
have demonstrated that established human cervical carcinoma cell
Fig. 5. Repression of E6 and E7 induces senescence in primary cervical carcinoma cells.
A) HFK, CVX-104, and CVX-106 cells at the indicated passage number were twice treated
with GM1 and infected with Pava encoding WT or K339M E2 at an MOI of 10. At nine
days post-infection, cells were ﬁxed and stained for SA-β-galactosidase activity. Similar
results were obtained for each cell type in at least two independent experiments. B)
Cells were infected as in panel A. Autoﬂuorescence was measured by ﬂow cytometry at
day seven post-infection. Similar results were obtained in three independent experi-
ments. Red, mock-infected; black, WT E2; green, K339M E2.
Fig. 6. Growth inhibition of primary cervical carcinoma cells is dependent upon repres-
sion of E6 and E7. A) CVX-104 cells infected with either empty retroviral vectors
(LXSN/RVY) or vectors encoding E2-resistant HPV16 E6 and HPV18 E7 genes (16E6/
18E7) were treated with GM1 and either mock-infected or infected with Pava as de-
scribed in Fig. 3A. DNA synthesis was measured as in Fig. 3A and is presented as the av-
erage of three independent experiments. The difference between DNA synthesis of
infected LXSN/RVY cells as a % of mock-infected cells and 16E6/18E7 infected cells as
a % of mock-infected cells was statistically signiﬁcant (*pb .05). B) Vector only or
16E6/18E7-expressing CVX-104 cells were treated with GM1 and infected with Pava
as described in Fig. 4A. Endogenous HPV18 E6 mRNA levels were measured by qRT-
PCR as described in Fig. 4A. Similar results were obtained in two independent
experiments.
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2000; Goodwin and DiMaio, 2000; Hwang et al., 1993; Jiang and
Milner, 2002; Parish et al., 2006), but these previous experiments
did not determine whether this requirement was an intrinsic proper-
ty of cervical cancer cells or whether it was acquired during the estab-
lishment or propagation of permanent cell lines. Because established
cancer cell lines, especially HeLa cells, diverge widely from tumors
and primary cancer cells (Carlson et al., 2007; Sandberg and Ernberg,
2005), it seemed prudent to examine the requirement of E6/E7 in low
passage human cancer cells. Furthermore, E6/E7 expression induces
human keratinocytes to become resistant to terminal differentiation
caused by high calcium and FBS (Munger et al., 1989; Pei et al.,
1998; Schlegel et al., 1988; Sherman and Schlegel, 1996), the condi-
tions typically used to culture established cervical cancer cell lines.
Therefore, these conditions may allow the proliferation of only
those cell that express E6 and E7. If this were the case, E6/E7 depen-
dence is not an intrinsic property of cervical cancer cells, but rather an
artifact of the cell culture conditions.
To determine whether cervical cancer cells have an intrinsic re-
quirement for HPV E6 and E7, we examined the behavior of low pas-
sage cervical cancer cells cultured under conditions that do not selectfor E6 and E7 expression. We isolated cells from primary cervical can-
cers, cultured them in serum-free keratinocyte media with low calci-
um, and, after a minimal number of passages, analyzed their
dependence on HPV E6 and E7. We believe that the early passage
numbers at which these cells were tested and the conditions used
to maintain them provide a better model for studying E6 and E7 de-
pendence than established cell lines or cells immortalized in vitro. Un-
fortunately, the original tumors from which our primary cervical
cancer strains were isolated no longer exist, so we cannot directly
compare them to the primary cell strains analyzed here.
Expression of BPV E2 in all four primary cervical carcinoma cell
strains repressed E6 and E7 and caused a signiﬁcant inhibition of
DNA synthesis (6- to 20-fold). Cancer cells as early as three passages
after isolation displayed this response. E2 expression had only a slight
effect on DNA synthesis of HPV-negative, primary HFFs and HFKs, and
a DNA binding-defective E2 mutant had a minimal effect on DNA syn-
thesis in the cancer cells. Moreover, growth arrest was abrogated by
exogenous copies of E6 and E7. These results demonstrate that the
ability of the E2 protein to bind to and repress the E6/E7 promoter
is essential for its ability to induce growth arrest in primary human
cervical cancer cells. Taken together, our results indicate that these
primary human cervical cancer cells are dependent on E6 and E7 as
early as three passages after isolation from patients and suggest that
some in vivo human tumors are also dependent on E6/E7 for growth.
However, even though the earliest passage cells we tested were high-
ly dependent on HPV E6/E7, we have not ruled out the possibility that
time in culture affects the sensitivity of cervical cancer cells to E6/E7
repression.
Repression of the E6 and E7 genes by the E2 protein in CVX-104 and
CVX-106 cells led to elevated levels of p53 and active, hypophosphory-
lated p105Rb. Levels of total p105Rb were not elevated in the primary
cervical cancer cells, unlike the situation in the established cell lines,
highlighting a biochemical difference between primary cells and estab-
lished cancer cell lines. In addition, E6/E7 repression in the primary
cells resulted in growth arrest, increased autoﬂuorescence and SA-β-
galactosidase activity, and cell enlargement and ﬂattening, all markers
of cellular senescence. These data imply that repression of E6 and E7 in
these primary cells induces senescence as a result of reactivation of p53
and p105Rb, as is the case in HeLa cells (DeFilippis et al., 2003). Senes-
cence in the primary cancer cells is not due to up-regulation of p16ink4a,
which is constitutively up-regulated in proliferating cervical cancer
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(unpublished data). Since senescence is irreversible (Campisi and
d'Adda di Fagagna, 2007), we infer that repression of E6 and E7 in pri-
mary cervical carcinoma cells induces permanent growth arrest.
Lambert and colleagues demonstrated that repression of HPV16
E7 in a transgenic mouse model of cervical cancer caused tumor re-
gression (Jabbar et al., 2009). Our results extend these ﬁndings from
mice to human cells from invasive cancers that had undergone the
decades-long process of carcinogenesis in women. The cellular basis
of tumor regression in the mouse system has not been established,
but in human cervical cancer cells, HPV repression causes senescence,
which, like cell transformation, is under markedly different control in
human and mouse cells (Balmain and Harris, 2000; Chaturvedi et al.,
2004; Dotto, 1998; Goodwin et al., 2000; Newbold, 1997; Rangarajan
et al., 2004). Nevertheless, the dependence on HPV oncogenes in pri-
mary human cervical cancer cells, established cervical cancer cell
lines (and HPV-associated head-and-neck cancer cell lines (Rampias
et al., 2009)) and transgenic mice indicates that oncogene depen-
dence is a fundamental feature of HPV-induced cancers.
It was previously shown that human keratinocytes immortalized
in vitro with transfected HPV16 DNA and maintained in the absence
of FBS and in low concentrations of calcium are dependent on E6
and E7 for continued growth (Lee et al., 2002). However, immortal-
ized cells are very different from cervical carcinoma cells. For exam-
ple, unlike cells derived from tumors, cells immortalized in vitro by
HPV are not tumorigenic in experimental animals (Durst et al.,
1987; Lee et al., 2002; Pirisi et al., 1987; Woodworth et al., 1988). Fur-
thermore, the vast majority of cervical high-risk HPV infections do
not progress to cancer, and when progression does occur, it typically
takes many years. These ﬁndings indicate that E6/E7 expression is not
sufﬁcient for tumorigenesis and that additional factors and genetic al-
terations are required for tumor formation in women. Thus, while it is
not surprising that cells recently immortalized with E6/E7 in vitro re-
tain their dependence on the proximal immortalizing agent, the rele-
vance of this ﬁnding to human cancer cells is unclear.
It is striking that cancer cells retain E6/E7 dependence despite the
onslaught of mutagenesis engendered by the viral oncoproteins. Re-
markably, this dependence on E6/E7 extends to established cervical
cancer cell lines such as HeLa, SiHa, CaSki, which have been exposed
to decades of stress and mutagenesis during time spent in culture. It
is possible that the viral oncogenes are more effective than acquired
mutations at inactivating cellular tumor suppressor pathways or acti-
vating mitogenic pathways, thereby eliminating selective pressure for
mutations in these pathways. However, expression of dominant-
negative p53 blocks p53 signaling more completely than expression
of HPV E6 (Butz et al., 1995). Rather, we propose that sustained de-
pendence on the viral oncogenes is a consequence of the multiplicity
of pathways that are targeted by the viral oncoproteins. For example,
in addition to the p53 pathway, the E6 protein targets telomerase,
several PDZ domain-containing proteins, and components of the
DNA repair and apoptosis machineries (Howie et al., 2009). Because
these multiple pathways are unlikely to be activated or inactivated
by mutations in one or a few cellular genes, viral proteins are more ef-
fective drivers of cell growth and survival than are randommutations
occurring in cellular DNA. This implies that therapies directed against
individual cellular pathways targeted by the viral oncoproteins are
likely to be less effective than therapies against the viral oncogenes
themselves.
We have been able to expand primary cultures with high purity
from 20-30% of cervical cancer tumor biopsies. Although this rate of
success is higher than in a previously reported attempt to culture cer-
vical carcinoma cells (Ku et al., 1997), we do not know if cervical car-
cinomas that fail to grow in culture also depend on E6 and E7.
Nevertheless, our data indicate that E6 and E7 dependence is an in-
trinsic property of cervical carcinoma cells from at least a substantial
fraction of patients and is not a trait that is acquired during theestablishment and propagation of permanent cell lines. These ﬁnd-
ings in turn imply that treatments that inhibit the expression or activ-
ity of E6 and E7 may have therapeutic beneﬁt in cervical cancer
patients. The cancer isolates we studied were from early stage carci-
nomas; additional studies should determine whether cells isolated
from advanced cervical carcinomas are also dependent on E6 and E7
for growth.
Our ability to infect these primary cancer cells with our E2 vector
was informed by an understanding of the factors that control SV40 in-
fection. The efﬁciency of SV40 infection appears to be dictated in large
part by levels of cell-surface GM1, which binds directly to the major
viral capsid protein, VP1 (Campanero-Rhodes et al., 2007; Neu et al.,
2008; Tsai et al., 2003). In our experiments, CVX-102 and HeLa-
Sen2 cells, which displayed the highest level of GM1, were efﬁciently
infected with SV40 and Pava, whereas cells with lower levels of GM1,
such as SiHa and CaSki cells and most primary cervical cancer cells,
were infected poorly unless supplemented with GM1. These results
demonstrated that infection by SV40 vectors can be improved by ad-
dition of GM1 to human cells.
There are reports that recombinant SV40 vectors and in vitro as-
sembled SV40 virus-like particles are capable of efﬁciently transduc-
ing many mammalian cell types (Kimchi-Sarfaty et al., 2004; Lund
et al., 2005; Strayer et al., 2005). However, by using quantitative mea-
sures of early viral gene expression, we found considerable differ-
ences in the ability of different cells to be infected by SV40 and
SV40-based vectors generated in permissive monkey cells. In fact,
seven of nine cell strains tested in this study infected poorly in the ab-
sence of GM1 supplementation. Similar differences have been docu-
mented by other groups in studies of the mechanism of SV40
infection, which identiﬁed GM1 as a cell surface receptor for this
virus (Campanero-Rhodes et al., 2007; Low et al., 2004; Tsai et al.,
2003). Our demonstration that different cell isolates display marked
differences in GM1 cell-surface levels provides an explanation, at
least in part, for these differences in infectivity. The addition of GM1
to the culture medium provides a simple and inexpensive method
to expand the tropism of SV40 and SV40-based vectors for gene trans-
fer and gene therapy applications.
Conclusions
Low passage human cervical carcinoma cell lines maintained in
serum-free medium in low calcium require sustained expression of
the human papillomavirus oncogenes for continuous proliferation.
Extinction of HPV oncogene expression in these cells causes cellu-
lar senescence.
Incubation of primary human cells with the ganglioside GM1 is a
simple method to improve infection efﬁciency by SV40 and SV40-
based viral vectors.
Materials and methods
Cells
CV-1, 293-T, and SiHa cells were purchased from American Type
Culture Collection (ATTC, Manassas, VA). CV-1 cells were cultured in
Minimal Essential Medium (MEM) Eagle, with 10% FBS, standard an-
tibiotics, 10 mM L-glutamine, and 10 mM HEPES pH 7.2 (standard
supplements). HeLa-Sen2 cells were described previously (Goodwin
et al., 2000). Normal diploid human foreskin ﬁbroblasts (HFF) were
obtained from the Yale Skin Diseases Research Center (YSDRC).
CMT4 cells were provided by Y. Gluzman. CMT-4, HeLa-Sen2, HFF,
293-T, and SiHa cells were cultured in Dulbecco's MEM (DMEM)
with standard supplements. CaSki cells were obtained from Michael
Reiss (University of Medicine and Dentistry of New Jersey) and cul-
tured in RPMI-1640 with standard supplements. Primary human fore-
skin keratinocytes (HFK) were obtained from YSDRC and cultured in
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ride, human keratinocyte growth supplement (Invitrogen, Carlsbad,
CA), and standard antibiotics in the absence of serum. Hybridomas
expressing PAb 108 mouse anti-large T antigen (purchased from
ATTC) and PAb 597 mouse anti-VP1 (obtained from Edward Harlow,
Harvard Medical School)) were cultured in DMEM plus 20% FBS and
standard supplements.
CVX-101 to CVX-106 cells were isolated from primary tumors as de-
scribed previously (Santin et al., 2005). Brieﬂy, viable tumor tissue was
harvested from solid tumor biopsies under sterile conditions at room
temperature. Samples were mechanically minced, washed with RPMI-
1640, and then incubated on a magnetic stirring apparatus in 0.14%
collagenase type I (Sigma-Aldrich Corp., St. Louis, MO) and 0.01%
DNAse (Sigma, 2000 kU/mg) in RPMI-1640 for 2 h at 37 °C or overnight
at 4 °C. Single cell suspensions were generated by ﬁltering
enzymatically-dissociated tumor through 150 μMnylonmesh, washing
in RPMI-1640 plus 10% human AB serum (Gemini Bioproducts, Calaba-
sas, CA), and culturing in keratinocyte serum-free media (KSFM) (Invi-
trogen, Carlsbad, CA) supplemented with 35–50 μg/ml bovine pituitary
extract, 5 ng/ml recombinant human EGF, 90 μM calcium chloride, and
standard antibiotics (KSFM+). We succeeded in establishing primary
cervical carcinoma cell strains in approximately 20-30% of attempts. Pu-
rity and homogeneity of fresh tumor cultures were tested by morphol-
ogy, immunohistochemistry staining and/or ﬂow cytometry with
antibodies against cytokeratins and p16ink4a (CDKN2). Only primary
cultures that had at least 95% viability and contained >99% epithelial
cells expressing p16 were used in the experiments described below.
HPV genotyping was conducted as described previously (Santin et al.,
2005). Primary cell strains were shown to be free of HeLa cell contami-
nation by using a PCR-based assay to detect a novel HeLa cell-speciﬁc
retro-transposon (Rahbari et al., 2009). All cell isolates and cell lines
were conﬁrmed to have originated from different patients by amplify-
ing and sequencing ﬁve genomic regions known to contain several sin-
gle nucleotide polymorphisms (SNPs). The protocol and results for this
analysis are available upon request. Cells were also found to be free of
mycoplasma by using Mycoscope PCR Detection Kit (Genlantis, San
Diego, CA) according to the manufacturer's instructions. Passage 0 of
primary cells is the point at which cells were placed in culture. A pas-
sage number was recorded each time a 70–80% conﬂuent 10 cm dish
of cells was passed 1:4. Cells were thawed, expanded, and analyzed at
the earliest passage available.
To generate cells that stably express exogenous HPV16 E6 and
HPV18 E7, CVX-104 cells were ﬁrst infected with the concentrated
LXSN or LXSN 16E6 retrovirus stocks (see below) in KSFM+and select-
edwith 35 μg/ml G418 for nine days. Cells were then infectedwith con-
centrated RVY or RVY 18E7 retrovirus and selected in 20 μg/ml
hygromycin for 12 days. Following selection, cells were maintained in
KSFM+ with 17.5 μg/ml G418 and 10 μg/ml hygromycin.
Reagents
Monosialoganglioside GM1 from bovine brain was purchased from
Sigma-Aldrich Corp. Alexa Fluor 488 donkey anti-mouse IgG (H+L)
and Alexa Fluor 488 Cholera Toxin B were purchased from Invitrogen.
Mouse monoclonal anti-human p105Rb and mouse monoclonal anti-
human p53 were purchased from BD Pharmingen (San Jose, CA). Goat
polyclonal anti-humanβ-actinwas purchased from Santa Cruz Biotech-
nology Inc (Santa Cruz, CA). RNeasy kits were purchased from Qiagen
(Valencia, CA). iScript cDNA synthesis and iQ SYBR Green Supermix
kits were purchased from BioRad (Hercules, CA). Tritiated thymidine
was purchased from MP Biomedicals (Solon, OH).
Viruses
WT SV40 strain 776 was generated from pBRSV DNA (obtained
from ATTC) in permissive CV-1 cells. A ﬁnal high titer stock wasgenerated using the Pava harvesting protocol as described previously
(Goodwin et al., 1998; Naeger et al., 1999). Titers of WT SV40 stocks
were determined by infecting CV-1 cells and measuring the fraction
of cells expressing large T antigen (see below) at 24 h post infection
by immunostaining and ﬂow cytometry. Prior to the generation of
SV40 virus from pBRSV DNA, a phenylalanine mutation at position
325 of VP1 found in pBRSV DNA was converted to WT serine by stan-
dard site-directed mutagenesis.
BPV1/SV40 recombinant viruses, designated Pava, which encode
WT or K339M BPV-E2 were generated and harvested as described
previously (Goodwin et al., 1998; Naeger et al., 1999). The E2 repres-
sor and E5 genes were disrupted in WT Pava vector but remained in-
tact in K339M Pava (described in Goodwin et al., 1998). Virus stocks
were titered by infecting CMT-4 cells with Pava and measuring the
fraction of cells that expressed VP1 by immunostaining and ﬂow cyto-
metry. The protocol used for measuring VP1 expression is identical to
the protocol used for measuring large T antigen expression (see
below), except cells were ﬁxed in 10% formaldehyde and permeabi-
lized in 10% formaldehyde with 0.2% triton X-100. PAb 597 mouse
anti-VP1 was used to measure VP1 expression.
Retroviruses expressing HPV16 E6 andHPV18 E7were described pre-
viously (DeFilippis et al., 2003; Halbert et al., 1991). Retrovirus stocks
were generated in 293-T cells as described previously (Yates et al.,
2008). Virus was harvested at 48 h post transfection and concentrated
with Peg-It (System Biosciences, Mountain View, CA) according to the
manufacturer's instructions. Brieﬂy, one volume of Peg-It was added to
four volumes of retrovirus at 4 °C overnight. Precipitated retrovirus was
pelleted by centrifugation, washed, and resuspended in KSFM+.
DNA synthesis
To measure DNA synthesis, an equal number of cells were plated
in triplicate. Cells were treated with 10 (HeLa, SiHa, CasKi) or 15 μg/
ml GM1 (all other cells) overnight in either the medium used to cul-
ture cells (keratinocytes and CVX-101 to CVX-106 cells) or DMEM
with 1% FBS (all other cells). Cells were then washed with PBS (kera-
tinocytes and CVX-101 to CVX-106 cells) or DMEM with 10% FBS (all
other cells lines) and either mock-infected or infected with Pava. At
the indicated time post-infection, cells were treated with media con-
taining 1.5 uCi of [3H]thymidine/ml for 5 to 6 h. After precipitating
nucleic acids with 10% trichloroacetic acid, DNA synthesis was deter-
mined by measuring the incorporation of [3H]thymidine into acid-
insoluble material using a liquid scintillation counter.
SDS-PAGE and immunoblotting
For immunoblotting, cells were harvested at the indicated times
post-infection and lysed on ice in NP40 buffer (50 mM TRIS pH 8.0,
1 mM EDTA, 150 mM NaCl, 1% NP40, 0.1% SDS, standard protease in-
hibitors) for 12 min. Debris was cleared by centrifugation, and equal
quantities of protein were electrophoresed on standard 7.5% or 12%
polyacrylamide gels containing SDS. After electrophoresis, proteins
were transferred to polyvinylidene ﬂuoride membranes (Millipore,
Billerica, MA) in transfer buffer (12.5 mM Tris, 0.1 M glycine, 20%
methanol) and blocked in 5% milk/TBST buffer (5% nonfat dry milk,
25 mM Tris–HCl [pH 8.0], 125 mM NaCl, 0.1% Tween-20). The mem-
branes were probed with the following speciﬁc antibodies: mouse
monoclonal anti-human p105Rb, mouse monoclonal anti-human
p53, or goat polyclonal anti-human β-actin.
Quantitative reverse transcriptase real-time PCR
Quantitative real-time PCR (qRT-PCR) and primer design were per-
formed as described previously (Johung et al., 2007). Brieﬂy, total RNA
was harvested using the RNeasy with DNAse treatment or RNeasy
Plus kit at indicated times post-infection. 1 μg RNA was used as a
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PCR was performed by using iQ SYBR Green Supermix with 40 ng
cDNA per 20 μl reaction and the BioRad MyiQ Single-color Real-time
PCR detection system. GAPDH transcripts were detected using primers
5’-CAGCCTCAAGATCATCAGCA-3’ and 5’-TGTGGTCATGAGTCCTTCCA-3’.
BPV-E2 transcripts were detected using 5’-GACGAGGCAGCCAGATT-
TAG-3’ and 5’ GGGTCTCCTTCAGGTCCTTC-3’. HPV16 E6/E7 transcripts
were detected using primers 5’-ACAAGCAGAACCGGACAGAG-3’ and
5’-GCCCATTAACAGGTCTTCCA-3’, which annealed to the E7 ORF present
in both transcripts. HPV18 E6/E7 transcripts were detected using
primers 5’-TGAAATTCCGGTTGACCTTC -3'and 5’-CACGGACACACAAAG-
GACAG-3’, which annealed to the E7 ORF present in both transcripts.
Exogenous HPV18 E7 transcripts were detected using primers 5’-
AAGCTCAGCAGACGACCTTC-3’ and 5’-CACAGCCGGATCAGCTTACT-3’,
which annealed to the E7 ORF and the 3'UTR of the RVY vector. Endog-
enous HPV18 E6/E7 transcripts were distinguished from exogenous
HPV18 E7 transcripts by using primers 5’-CCAGAAACCGTTGAATCCAG-
3'and 5’-GTTGGAGTCGTTCCTGTCGT-3’, which annealed to the HPV18
E6 ORF present in both endogenous transcripts but absent from the ex-
ogenous E7 ORF.
SV40-infection and ﬂow cytometry of large T antigen
Cells were treated with GM1 as described above and infected with
SV40 at the indicated MOI. At 48 h post-infection, cells were trypsi-
nized, neutralized, and washed once with PBS. Cells were then ﬁxed
by adding ice cold methanol dropwise to the cell pellet while vortex-
ing gently, and the ﬁxation continued for at least 20 min on ice. After
centrifugation, methanol was removed, and cells were blocked for
5 min in PBS plus 0.5% bovine serum albumin (BSA). The cell pellet
was then resuspended in 100 μl of a 1:1 mixture of 5% normal donkey
serum in PBS (NDS-PBS) to PAb 108 monoclonal mouse anti-large T
antigen supernatant and incubated for 1 h at 37 °C. The cells were
then washed twice with PBS+0.5% BSA and resuspended in 100 μl
NDS-PBS containing a 1:500 dilution of Alexa Fluor 488 donkey
anti-mouse IgG and incubated at 37 °C for 30 min. Following two
washes in PBS+0.5% BSA, the cell pellet was resuspended in 200 μl
PBS and kept on ice until analysis. The fraction of cells expressing
large T antigen was measured using a 488 nm excitation and
530 nm emission ﬁlter on a FACS Calibur ﬂow cytometer (BD Biosci-
ences, San Jose, CA) and plotted on a 650 nm vs 530 nm emission ﬁl-
ter 2D-density plot.
Cholera toxin B binding
Cells were mock-treated or treated with GM1 as described above.
After removing unincorporated GM1, cells were trypsinized, neutral-
ized, and washed once with ice cold PBS. Cells were then resuspended
in 500 μl of ice cold DMEMwith 1 μg/ml Alexa Fluor 488 labeled chol-
era toxin B (CTXB) and incubated at 4 °C for 30 min. Cells were then
washed twice in cold PBS, resuspended in PBS, and kept on ice until
analysis. CTXB binding was analyzed using a 488 nm excitation and
530 nm emission ﬁlter on a FACS Calibur ﬂow cytometer.
Senescence assays
To assess autoﬂuoresence and/or granularity, cells were treated
with GM1 and infected with Pava at the indicated MOI as described
above. Where indicated, the process was repeated a second time to
reduce the number of cells that escaped infection. At the indicated
times after the ﬁrst infection with Pava, autoﬂuoresence was mea-
sured by ﬂow cytometry of unstained cells using 488 nm excitation
and a 650 nm emission ﬁlter on a FACS Calibur ﬂow cytometer. Gran-
ularity was measured using a 488 nm laser and side scatter channel
(SSC). For measuring senescence-associated (SA)-β-galactosidase,
cells were treated with GM1 and infected with Pava twice as above.Nine days after the ﬁrst infection, SA-β-galactosidase staining was
performed as described previously (Dimri et al., 1995; Goodwin et
al., 2000).
Statistical analysis
A two-tailed T-test was used for all statistical analysis of data.
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